Biotech Stock Alert for AVI BioPharma Inc. Issued by Beacon Equity
March 18 2010 - 6:50AM
BeaconEquity.com announces an investment report featuring biotech
company AVI BioPharma Inc. (Nasdaq:AVII). The report includes
financial, comparative and investment analyses, and pertinent
industry information you need to know to make an educated
investment decision.
The full report is available at:
http://www.beaconequity.com/i/AVII
Get our alerts BEFORE the rest of the market. Follow us on
Twitter: http://twitter.com/BeaconEquity
AVI BioPharma Inc. (AVII) is a biopharmaceutical company
specializing in the discovery and development of ribonucleic acid
(RNA)-based drugs targeting a range of diseases. The Company has
developed and optimized derivatives of its antisense chemistry
(phosphorodiamidate morpholino oligomers (PMOs)) that can be
designed to target disease mechanisms through mechanisms of action.
Message Board Search for AVII:
http://www.boardcentral.com/boards/AVII
In the report, the analyst notes:
"Revenues for the fourth quarter of 2009 were $5.1 million,
compared to $5.5 million in the fourth quarter of 2008. Revenues
for the full year ended December 31, 2009, were $17.6 million,
compared to $21.3 million in the full year ended December 31, 2008,
reflecting decreases in research contract revenues of $3.7
million.
"AVII recently announced that CureDuchenne and the Foundation to
Eradicate Duchenne (FED) each awarded grants of $250,000 to AVII to
support continued research and development of the Company's exon
skipping drug candidates for the treatment of Duchenne Muscular
Dystrophy (DMD), a genetic muscle wasting disease caused by failure
to produce dystrophin. CureDuchenne and FED are U.S. not-for-profit
foundations fully dedicated to supporting the research and
development of a cure for DMD."
To read the entire report visit:
http://www.beaconequity.com/i/AVII
See what investors are saying about AVII at penny stock
forum
BeaconEquity.com is one of the industry's largest small-cap
report providers. Beacon strives to provide a balanced view of many
promising small-cap companies that would otherwise fall under the
radar of the typical Wall Street investor. We provide investors
with an excellent first step in their research and due diligence by
providing daily trading ideas, and consolidating the public
information available on them. For more information on Beacon
Research, please visit http://www.BeaconEquity.com
Beacon Equity Disclosure
DO NOT BASE ANY INVESTMENT DECISION UPON ANY MATERIALS FOUND ON
THIS REPORT. We are not registered as a securities broker-dealer or
an investment adviser either with the U.S. Securities and Exchange
Commission (the "SEC") or with any state securities regulatory
authority. We are neither licensed nor qualified to provide
investment advice. Beacon Equity Research nor its affiliates have a
beneficial interest in the mentioned company; nor have they
received compensation of any kind for any of the companies listed
in this communication. The information contained in our report is
not an offer to buy or sell securities. We distribute
opinions, comments and information free of charge exclusively to
individuals who wish to receive them.
CONTACT: Beacon Equity Research
Jeff Bishop
(469)-252-3505
press@beaconequity.com
Avi Biopharma (NASDAQ:AVII)
Historical Stock Chart
From May 2024 to Jun 2024
Avi Biopharma (NASDAQ:AVII)
Historical Stock Chart
From Jun 2023 to Jun 2024